The latest happenings in the clinical trials industry from the past month, all in one place.
Walter Tyrrell
Inteliquet welcomed Marie E. Lamont as Interim President and Chief Operating Officer.
Sharp has strengthened its senior leadership team with two new additions. Walter Tyrrell has been appointed as Chief Financial Officer, and Robert O’Beirn as Senior Vice President and Commercial Director.
Parexel announced the appointment of four key experts to its Regulatory Consulting group. The new Technical Vice Presidents are Mark Birse, Philip E.M. Crooker, Lynne A. Ensor PhD, and Yuexia Li PhD.
Rho announced Dr. Meagan E. Spychala has been promoted to Assistant Vice President of Patient Engagement and Program Strategy.
MMS Holdings announced that its regional operations in South Africa has more than doubled in the past fiscal year through the addition of new colleagues in Bloemfontein and the procurement of contracts with clinical trial sponsors and research groups.
PRISYM ID announced that its life sciences dedicated labelling solution, PRISYM 360, will be part of a clinical trials handling system for the Medicines Manufacturing Innovation Center project.
ERT announced it has reached the significant milestone of more than 10,000 clinical studies across all phases of clinical development.
Teckro has added two new software products, Teckro Engage and Teckro Survey.
Clinerion’s global hospital network has expanded Armenia with Arabkir Joint Medical Center& Institute of Child and Adolescent Health joining their Patient Network Explorer platform.
Inteliquet has announced a significant milestone in modernizing patent recruitment for clinical trials- digitizing more than 250 clinicaltrials protocols and proactively identifying 1,000 patients eligible for participation oncology clinical trials.
WuXi Biologics announced that its subsidiary WuXi Vaccines, is to invest $240 million and build a new vaccine manufacturing facility in Ireland.
Clinerion partnered with Eugen to expand Patient Network Explorer coverage to patients and hospitals in Uruguay.
Clinerion is also partnered with EvidNet throughout the South Korea and Asia-Pacific region.
PHARMASEAL team at 2019 Medilink East Midlands Business Awards
PHARMASEAL announced that is has won Start-Up of the Year in the 2019 Medilink East Midlands Business Awards.
PPD, Inc. has been selected by Medidata to receive its Patient First Award.
The first NHS Trust has been awarded IAOCR’s Clinical Research Site Workforce Quality Accreditation.
Almac Group has been awarded $1 million by the Bill & Melinda Gates Foundation.
PHASTAR has gained its 2020 Star rating based on the Best Companies’ Index score.
Almac Group is delighted to announce Almac has won the “Innovation in Sponsorship” award during this year’s Irish Sponsorship Awards ceremony in Dublin.
Advanced Clinical announced Clinical Research Executive Julie Ross has received the 2019 Healthcare Businesswomen’s Association Chair Award.
Clinerion has been certified byEuropean Health Data & Evidence Network to map health data from various formats to the OMOP common data model.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.